Table of Contents
This technology scouting case study follows a mid-size biopharma’s search for an external delivery platform to carry its gene-editing payloads in vivo — the bottleneck standing between its pipeline and the clinic. Rather than fund a multi-year internal programme, its corporate-development team asked us to scout the world for a partner or licensable asset that could close the gap faster.
The Challenge
The client had a validated gene-editing payload and no reliable way to deliver it to the target tissue. In-house work on lipid nanoparticles had stalled, and the leadership question had shifted from “can we build this” to “who has already solved it, and can we access their platform before a competitor does.”
Biotechnology is a fast-moving field to scout. EPO biotechnology filings rose 5.4% to 8,479 in 2024, extending an uptrend that now spans at least eight years, per the EPO Patent Index 2024 — meaning the relevant art was both large and still growing quickly. Delivery science in particular spans several modalities at once: lipid nanoparticles, adeno-associated virus vectors, cell-penetrating peptides and newer polymer systems, each with a different maturity and IP position.
The team needed more than a list of companies. It needed to know which platforms were technically fit for its payload and tissue target, how mature each was, who owned the underlying IP, and which could realistically be accessed by licence or partnership rather than acquisition.
Our Approach
We ran the engagement through our standard technology scouting method, adapted to the biology.
First we fixed a need statement both R&D and business development signed off on: the tissue target, the payload class, the delivery efficiency threshold and the access constraint (licence or partnership, not acquisition). That single page kept the search pointed at an answer the client could act on.
We then scanned three signal layers in parallel:
- Patents — delivery-platform families at the EPO, USPTO and via PCT, read for assignee, maturity and claim scope
- Scientific literature — recent delivery-efficiency results and the groups producing them, as an early indicator ahead of filings
- Startups and translational programmes — spin-outs and academic platforms not yet visible in issued patents
Every candidate was scored on a common scorecard — technical fit to the payload and tissue, platform maturity, strength and ownership of the IP position, and the realistic access route — so a heterogeneous field could be ranked on one comparable basis.
Finally, we ran an IP overlay on the finalists, flagging blocking families and freedom-to-operate risk so the shortlist reflected not just the best science but the assets the client could actually license and practise.
What the Research Found
Reading the delivery landscape through a life-cycle lens changed the shortlist. The most-publicised lipid-nanoparticle approaches sat in a crowded, maturing part of the curve with dense, heavily-cross-licensed IP — a poor place to enter as a late partner. Two quieter sub-fields, by contrast, showed the new-entrant and citation signals of a field still in its growth phase, where an access deal would be cheaper and less contested.
The scan surfaced 40-plus assets and narrowed to five partners: two established platform companies with proven but expensive IP, and three earlier-stage academic and spin-out programmes with strong fit and open licensing paths. Three emerging sub-fields were flagged as ones to watch, each identified from steepening filing velocity and fresh assignees before the absolute counts made the trend obvious.
The literature layer earned its place here. Two of the three earlier-stage programmes were producing strong delivery-efficiency results in peer-reviewed work but had only thin patent coverage so far — invisible to a patent-only search, yet exactly the kind of open, growth-phase asset the client wanted. Reading papers alongside filings is what surfaced them while an access deal was still cheap.
The Outcome
The client received a ranked, IP-checked shortlist of five accessible delivery platforms, each with a defined route in — licence, research collaboration or option-to-acquire — and a one-page rationale tying the science, the maturity and the IP position together.
That turned an open-ended internal debate into a focused set of partnering conversations. Instead of committing several years and a large internal budget to rebuild delivery science from scratch, the team could open discussions with a handful of pre-vetted partners and time its move while the most promising sub-fields were still early enough to enter on favourable terms.
What This Means for Similar Matters
The value of technology scouting in biotech comes from reading maturity, not counting patents. The crowded, obvious modality was the weakest place to enter; the platforms worth pursuing were the ones whose curves were still steepening.
A disciplined need statement is what makes a heterogeneous delivery field rankable — without an agreed threshold and access constraint, forty candidates stay forty opinions. And screening for IP access alongside technical fit stops a scouting exercise from shortlisting a platform the client could admire but never practise.
Why the Obvious Modality Was the Wrong Answer
The instinctive move in a delivery search is to chase the most-cited, best-funded approach. In this engagement that approach sat in a maturing, densely cross-licensed part of the curve, where a late entrant would pay the most and control the least. Reading each modality’s S-curve position, rather than its headline profile, is what redirected the search toward fields still open enough to enter on favourable terms.
How This Connects to Forecasting and Sizing
Scouting rarely stands alone. The same maturity read that ranked these platforms feeds a technology forecast of where the modality is heading, and the shortlist naturally raises the next question of how large the addressable opportunity is. Clients frequently pair a scout with a forecast and a market-sizing pass so the sourcing decision and the investment case are built on one consistent evidence base.
In this matter the client took exactly that path. Having narrowed to five partners, the team commissioned a short forecast on the two growth-phase sub-fields to confirm they had several years of runway left before consolidation, and a sizing pass on the lead indication to underwrite the deal economics. Because all three exercises drew on the same filing and citation dataset, the numbers reconciled instead of contradicting each other in the investment committee.
Data Sources
The market and patent data referenced above comes from:
- EPO Patent Index 2024 — Biotechnology filing growth (+5.4% to 8,479) used to frame the scale of the art.
- WIPO World Intellectual Property Indicators 2024 — Global filing and grant baseline for reading relative filing velocity.
- Daim et al., Forecasting emerging technologies (Technological Forecasting & Social Change) — Method for combining bibliometric and patent signals to detect emerging sub-fields.
Discuss a Similar Scouting Matter
Tell us the technology gap you need to close, and we will scout the world for the partners who can close it.
Discuss a Similar Scouting Matter
Related PerspireIP work: Technology Scouting service · Technology Forecasting.
Frequently Asked Questions
Is this technology scouting case study a real client engagement?
It is a representative scenario built from our standard scouting method and from publicly verifiable biotech filing data, not a named client account. The workflow, scorecard and signal layers are exactly what we run; the specific figures illustrate how the method behaves rather than reporting one confidential matter.
How long does a technology scouting engagement like this take?
A focused scout of a single modality typically runs eight to twelve weeks from an agreed need statement to a ranked, IP-checked shortlist. A broader mandate spanning several modalities takes longer, mainly in the scoring and IP-overlay stages.
Why include an IP overlay in technology scouting?
Because the best science is worthless if you cannot practise it. Screening finalists for blocking patent families and freedom-to-operate risk ensures the shortlist reflects platforms the client can actually license and use, not just admire from a distance.
How does scouting decide which delivery platforms to prioritise?
Each candidate is scored on one scorecard: technical fit to the payload and tissue target, platform maturity on its life-cycle curve, strength and ownership of the IP, and a realistic access route. Ranking a heterogeneous field on common criteria is what makes the shortlist defensible.
Can scouting find opportunities before they show up in patents?
Yes. Scientific literature and startup activity often signal a promising platform before issued patents appear, which is why we scan all three layers in parallel rather than relying on patents alone.